Market Overview:

The recent report by Market Research Future (MRFR) asserts that the global Parkinsons Disease Therapeutics market 2020 is slated to acquire a substantial market valuation at a moderate CAGR over the review period.

Global Parkinsons Disease Therapeutics Market is anticipated to witness significant growth, owing to the increasing cases of Parkinsons disease, with the growth in aging population levels. Furthermore, increasing environmental factors & genetic heredity is augmenting the growth of Parkinsons disease therapeutics market. Therefore, it may drastically result in expanding the market size during the forecast period. Pharmaceutical firms are creating new and improved therapies for Parkinson's disease (PD), and lately, there have been some significant product launches in Parkinson's disease therapeutics and other assistive therapeutics. Additionally, most of the global firms have a healthy drug pipeline for the treatment of Parkinson's disease, and as per the estimations, the forecast period may observe the launch of a few blockbuster drugs.

Additionally, the Parkinson's Disease Therapies Market is growing due to rising environmental variables and genetic heredity. However, the risk of Parkinson's disease rises with age, and the disease occurs most frequently in people over 50.

Segmental Analysis

The global Parkinsons disease therapeutics market is analyzed on the basis of type, treatment, and end-user. 

The global Parkinsons disease therapeutics market, based on the treatment type, is bifurcated into medication and surgical therapy. The medication segment is segmented further into COMT inhibitors, peripheral decarboxylase inhibitors, MAO inhibitors, dopamine precursors, and others. Surgery therapy is further bifurcated into deep brain stimulation (DBS) and carbidopa/levodopa enteral suspension.

On the basis of end-user, the Parkinsons Disease Therapeutics market is categorized into hospitals & clinics, academic & industrial research, and others.

Detailed Regional Analysis
The geographical analysis of the Global new parkinson drug  has been conducted in four major regions, namely the Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa.

Parkinsons disease therapeutics market is led by North America owing to the rising healthcare spending that contributes to improving the market growth in this region. The total number of Parkinsons disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Additionally, the high cost of Parkinson's disease therapeutics in the United States also leads to significant market size in terms of revenue.

It is projected that Europe stands second in the global Parkinsons disease therapeutics market. The increasing government initiatives to promote the healthcare sector and augmented adoption of research and development projects for chronic diseases in the healthcare domain fuel the market in this region. Moreover, the entry of market players into strategic partnerships and collaborations with the chemical industry drives the growth of the market in Europe.

The Asia Pacific is likely to observe growth in the Parkinsons disease therapeutics market during the review period due to the rising number of healthcare organizations, growing prevalence of Parkinsons disease. Moreover, the growing incidence of the geriatric population in the region influence market growth. India, China, and Japan are the key market players in this region, and the Asia Pacific is valued to be the fastest-growing market for Parkinsons disease therapeutics.

The Middle East and Africa hold the least share in the global Parkinsons disease therapeutics market due to the incidence of stringent government policies and weak economies.

Competitive Analysis:

• Salix Pharmaceuticals
• GlaxoSmithKline Plc
• Impax Laboratories, LLC
• Teva Pharmaceutical Industries Ltd
• Novartis AG, Orion Corporation
• Mylan N.V.
• Par Pharmaceutical
• Cipla Inc.
• Daiichi Sankyo
• Apotex Inc.
• Wockhardt Limited

The important contenders in the Parkinson's disease therapeutics market are GlaxoSmithKline Plc, Novartis AG, Impax Laboratories, LLC, Salix Pharmaceuticals, Apotex Inc., Teva Pharmaceutical Industries Ltd, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, and Wockhardt Limited.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com